Kiniksa Pharmaceuticals (KNSA) stock rocketed higher on Tuesday following the release of the biopharmaceutical company’s Q1 2026 earnings report. The company reported diluted earnings per share of 27 cents, which beat Wall Street’s estimate of 20 cents. It was also a roughly 145.5% increase year-over-year from 11 cents.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Kiniksa Pharmaceuticals also reported revenue of $214.27 million, which was another beat compared to the analyst estimate of $206.11 million. The company’s revenue also grew about 55.5% from the $137.79 million reported in Q1 2025. Kiniksa Pharmaceuticals chairman and CEO Sanj Patel said, “As the first quarter progressed, growth was observed in both new and repeat prescribers, providing momentum for our ARCALYST franchise for the rest of the year.”
Kiniksa Pharmaceuticals stock was up 10.2% in premarket trading on Tuesday, following a 1.92% rally yesterday. The shares have also increased 5.72% year-to-date and 68.51% over the past 12 months.
Kiniksa Pharmaceuticals Guidance
Kiniksa Pharmaceuticals provided investors with updated guidance in its most recent earnings report. The company expects:
- 2026 ARCALYST net product revenue between $930 million and $945 million, compared to prior guidance of between $900 million and $920 million.
- The company also expects its current operating plan to remain cash flow positive on an annual basis.
Is Kiniksa Pharmaceuticals Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts’ consensus rating for Kiniksa Pharmaceuticals is Strong Buy, based on six Buy ratings over the past three months. With that comes an average KNSA stock price target of $58.50, representing a potential 34.14% upside for the shares. These ratings and price targets will likely change as analysts update their coverage after today’s earnings report.
